Published with the inputs from Dr. Salal N, Specialist - Interventional Radiology, Meitra Hospital, Kozhikode
Transarterial Chemoembolisation (TACE) is a minimally invasive, image-guided procedure used to treat liver cancer (hepatocellular carcinoma) and some metastatic tumors. It combines chemotherapy and embolisation, delivering anti-cancer drugs directly into the tumor’s blood supply while blocking blood flow to the tumor — effectively starving it of oxygen and nutrients.
TACE is performed by interventional radiologists and is an excellent option for patients who are not suitable for surgery or liver transplantation.
TACE is a targeted therapy that delivers high doses of chemotherapy directly into the blood vessels feeding a tumor in the liver. Tiny particles (embolic agents) are then injected to block the blood supply, trapping the drug in the tumor for maximum effect.
TACE is primarily used for:
TACE is minimally invasive and not painful during the procedure due to local anesthesia. Some patients may experience mild post-procedure discomfort, low-grade fever, or fatigue — commonly referred to as post-embolisation syndrome, which subsides within a few days.
Yes. TACE is a safe and well-established treatment for liver cancer when performed by skilled interventional radiologists. Risks are rare and may include temporary nausea, pain, or mild liver function changes, which are carefully managed with medications and monitoring.
TACE may not be recommended if you have:
Your oncology team will evaluate your overall health and liver function before planning the procedure.
If you or a loved one has been diagnosed with liver cancer or metastatic tumors, the Interventional Radiology & Oncology Team at Baby Memorial Hospital (BMH) offers advanced Transarterial Chemoembolisation (TACE) — combining precision, safety, and proven outcomes for liver-directed cancer treatment.
👉 Book an Appointment Online or visit BMH to consult our interventional oncology specialists.